BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Andrea VisentinSilvia ImbergamoEdoardo ScomazzonStefano PravatoFederica FrezzatoLaura BonaldiMarco PizziStefania VioMichele GregianinMarta BureiMonica FaccoGianpietro SemenzatoFrancesco PiazzaLivio TrentinPublished in: British journal of haematology (2018)